Proton therapy systems market seen reaching $2.22 billion by 2030

The Business Research Company says the proton therapy systems market will grow from $1.58 billion in 2026 to $2.22 billion by 2030, driven by rising cancer cases and demand for more precise radiation therapy. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Proton therapy systems are gaining traction because they can target tumors more precisely than traditional radiation and limit damage to healthy tissue. - The market outlook points to continued investment in advanced cancer treatment infrastructure, especially as hospitals expand precision oncology capabilities. - Rising cancer incidence is a major demand driver for radiation oncology technologies.

What happened: - The Business Research Company published a 2026 market report on proton therapy systems. - The report estimates the market will rise from $1.58 billion in 2026 to $2.22 billion by 2030. - The forecast implies an 8.9% compound annual growth rate through 2030. - The report also says the market reached $1.43 billion in 2025 and is expected to grow to $1.58 billion in 2026, a 10.5% CAGR in that period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Proton therapy systems use proton beams to deliver radiation directly to tumor sites. - The targeted approach is designed to reduce harm to adjacent healthy tissue and lower side effects compared with conventional radiation. - Growth has been supported by more cancer cases, more multi-room proton therapy centers in hospitals, early clinical success in pediatric and complex tumors, expanding oncology infrastructure, and wider awareness of lower toxicity. - The forecast points to stronger demand for image-guided and adaptive proton therapy technologies. - The report expects wider adoption of compact, single-room proton therapy units. - The report highlights rising treatment volumes in lung, breast and gastrointestinal cancers. - The report also points to broader access in emerging healthcare markets and more investment in precision oncology and advanced radiotherapy platforms. - Key trend areas include integration with CT and PET scanners, smaller facility installations, and more use in brain, head and neck, and prostate cancers. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says its 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - The report offers a free sample at Download a free sample of the proton therapy systems market report. - The full report is available View the full proton therapy systems market report.

Between the lines: - The report’s growth story is tied to two forces at once: more cancer diagnoses and better technology that makes proton therapy more practical for hospitals. - The shift toward compact, single-room systems suggests the market may move beyond a few large specialty centers and into broader clinical use. - The regional split suggests mature adoption in North America and faster buildout in Asia-Pacific, where health systems are still scaling advanced oncology capacity. - The mention of image-guided therapy and scanner integration signals that hardware alone is no longer the main selling point; workflow and precision features matter more.

What's next: - The market is expected to keep expanding through 2030 as more patients are treated with proton therapy across additional cancer types. - Adoption should rise as hospitals invest in smaller installations and more advanced radiotherapy platforms. - The next competitive focus is likely to center on precision, accessibility and integration with imaging systems.

The bottom line: - Proton therapy systems are moving from niche oncology technology toward broader clinical adoption, with growth driven by cancer burden, precision-treatment demand and more deployable equipment designs.